SavedAdd your journal

Journals / Turkish Journal of Chemistry / 2014 / Cilt: 38 - Sayı: 2

Synthesis, biological evaluation, and molecular docking of ′ N -(Aryl/alkylsulfonyl)-1-(phenylsulfonyl) piperidine-4-carbohydrazide derivatives

Rashad HUSSAIN
Khalid MOHAMMAD KHAN
Muhammed ASHRAF
Syeda Abida EJAZ
Muhammad Qaiser FATMI
Hira KHALID
Aziz UR REHMAN
Muhammad Athar ABBASI
Pages
189–201
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Both studies confirmed the potential of compounds as excellent inhibitors for AChE and BChE.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:′A series of new N -[(alkyl/aryl)sulfonyl]-1-(phenylsulfonyl)piperidine-4-carbohydrazide derivatives were syn- thesized.
📊
Key Findings & Data:Starting from ethyl piperidine-4-carboxylate (a), first ethyl 1-(phenylsulfonyl)piperidine-4-carboxylate (1), sec- ′ond 1-(phenylsulfonyl)piperidine-4-carbohydrazide (2), and finally N -[(alkyl/aryl)sulfonyl]-1-(phenylsulfonyl)piperidine- 4-carbohydrazides (4a n) were synthesized by reacting 2 with alkyl/aryl sulfonyl chlorides (3a n).
💡
Conclusion & Impact:Both studies confirmed the potential of compounds as excellent inhibitors for AChE and BChE.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

′A series of new N -[(alkyl/aryl)sulfonyl]-1-(phenylsulfonyl)piperidine-4-carbohydrazide derivatives were syn- thesized. Starting from ethyl piperidine-4-carboxylate (a), first ethyl 1-(phenylsulfonyl)piperidine-4-carboxylate (1), sec- ′ond 1-(phenylsulfonyl)piperidine-4-carbohydrazide (2), and finally N -[(alkyl/aryl)sulfonyl]-1-(phenylsulfonyl)piperidine- 4-carbohydrazides (4a n) were synthesized by reacting 2 with alkyl/aryl sulfonyl chlorides (3a n). The structures of 1 the synthesized compounds were characterized by IR,H-NMR, and EI-MS spectra and all were screened in vitro for their acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzyme inhibition activities. Molecular docking was accomplished for these compounds to examine their binding interactions with AChE and BChE human proteins. The strategy we applied for this purpose was a direct receptor-based approach. The binding modes of the inhibitors under study were determined using an automated docking program (AutoDock) and were compared with antienzymatic IC 50 values. Both studies confirmed the potential of compounds as excellent inhibitors for AChE and BChE.

🔖

Cite This Article

HUSSAIN, R., KHAN, K. M., ASHRAF, M., EJAZ, S. A., FATMI, M. Q., KHALID, H., REHMAN, A. U., ABBASI, M. A. (2022). Synthesis, biological evaluation, and molecular docking of ′ N -(Aryl/alkylsulfonyl)-1-(phenylsulfonyl) piperidine-4-carbohydrazide derivatives. Turkish Journal of Chemistry, Cilt: 38 - Sayı: 2, 189–201. https://ajindex.com/articles/589532

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Massoulie, J.; Pezzementi, L.; Bon, S.; Krejci, E.; Valette, F. M. Prog. Neurobiol. 1993, 41, 31–91. Chatonnet, A.; Lockridge, O. Biochem. J. 1989, 260, 625–634. Cokugra ̧s, N. A. Turk. J. Biochem. 2003, 28, 54–61. Sussman, L. J.; Harel, M.; Frolow, F.; Oefner, C.; Goldman, A.; Toker, L.; Silman, I. Protein Sci. 1991, 253, 872–878. Gilman, A. G.; Rall, T. W.; Nies, A.; Taylor, P. In The Pharmacological Basis of Therapeutics; Eds. Pergamon, New York 1990, pp. 131–149. Hallak, M.; Giacobini, E. Neuropharmacology 1989, 28, 199–206. Scarpini, E.; Scheltens, P.; Feldman, H. Lancet Neurol. 2003, 2, 539–547. Perry, E. K.; Tomlinson, B. E.; Blessed, G.; Bergman, K.; Gibson, P. H.; Perry, R. H. Brit. Med. J. 1978, 25, 1457–1459. Holzgrabe, U.; Kapkova, P.; Alptuzun, V.; Scheiber, J.; Kugelmann, E. Expert. Opin. Ther. Targets 2007, 11, 161–179. Butini, S.; Campiani, G.; Borriello, M.; Gemma, S.; Panico, A.; Persico, M.; Catalanotti, B.; Ros, S.; Brindisi, M.; Agnusdei, M.; et al. J. Med. Chem. 2008, 51, 3154–3170. Bartolini, M.; Bertucci, C.; Cavrini, V.; Andrisano, V. Biochem. Pharmacol. 2003, 65, 407–416. Shafferman, A.; Velan, B.; Ordentlich, A.; Kronman, C.; Grosfeld, H.; Leitner, M.; Flashner, Y.; Cohen, S.; Barak, D.; Ariel, N. EMBO J. 1992, 11, 3561–3568. Changeux, J. P. Mol. Pharmacol. 1966, 2, 369–392. Cochard, P.; Coltey, P. Dev. Biol. 1983, 98, 221–238. Chatonnet, A.; Lockridge, O. Biochem. J. 1989, 260, 625–634. Sikorav, J. L.; Krejci, E.; Massoulie, J. EMBO J. 1987, 6, 1865–1873. Solis, A.; Nava, A.; Perez, H. I.; Manjarrez, N.; Luna, H.; Cassani, J. J. Mex. Chem. Soc. 2008, 52, 181–184. Khalid, H. Aziz-ur-Rehman; Abbasi, M. A.; Khan, K. M. Int. J. Pharm. Pharm. Sci. 2012, 4, 443–448. Aziz-ur-Rehman; Nafeesa, K.; Abbasi, M. A.; Khalid, H.; Khan, K. M.; Ashraf, M.; Ahmad, I.; Ejaz, S. A. Asian. J. Pharm. Hea. Sci. 2012, 2, 370–376. Aziz-ur-Rehman; Siddiqui, S. Z.; Abbas, N.; Abbasi, M. A.; Khan, K. M.; Shahid, M.; Mahmood, Y.; Akhtar, N. M.; Lajis, N. H. Int. J. Pharm. Pharm. Sci. 2012, 4, 676–680. Ellman, G. L.; Courtney, K. D.; Andres, V.; Featherstone, R. M. Biochem. Pharmacol. 1961, 7, 88–95. Kryger, G.; Harel, M.; Giles, K.; Toker, L.; Velan, B.; Lazar, A.; Kronman, C.; Barak, D.; Ariel, N.; Shafferman, A.; et al. Acta. Crystallogr. D. 2000, 56, 1385–1394. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. J. Comput. Chem. 2004, 25, 1605–1612. Humphrey, W.; Dalke, A.; Schulten, K. J. Mol. Grap